| Primary |
| Product Used For Unknown Indication |
22.2% |
| Hepatitis C |
11.1% |
| Osteomyelitis |
11.1% |
| Dialysis |
8.3% |
| Nephrogenic Anaemia |
8.3% |
| Hepatitis |
5.6% |
| Hypercholesterolaemia |
5.6% |
| Plasma Cell Myeloma |
5.6% |
| Renal Failure Chronic |
5.6% |
| Anaemia Neonatal |
2.8% |
| Blood Count Abnormal |
2.8% |
| Haemoglobin Decreased |
2.8% |
| Haemolytic Uraemic Syndrome |
2.8% |
| Nephrogenic Anemia |
2.8% |
| Renal Transplant |
2.8% |
|
| Anaemia |
10.0% |
| Hypertension |
10.0% |
| Rhabdomyolysis |
10.0% |
| T-lymphocyte Count Abnormal |
10.0% |
| Convulsion |
5.0% |
| Coronary Artery Stenosis |
5.0% |
| Drug Resistance |
5.0% |
| Haemoglobin Decreased |
5.0% |
| Hypertensive Encephalopathy |
5.0% |
| Myocardial Infarction |
5.0% |
| Nephrogenic Systemic Fibrosis |
5.0% |
| Pain |
5.0% |
| Purpura Neonatal |
5.0% |
| Rash Macular |
5.0% |
| Renal Failure |
5.0% |
| Stupor |
5.0% |
|
| Secondary |
| Drug Use For Unknown Indication |
15.9% |
| Product Used For Unknown Indication |
13.4% |
| Breast Cancer |
10.3% |
| Lung Neoplasm Malignant |
10.1% |
| Anaemia |
7.8% |
| Coronary Artery Disease |
7.5% |
| Nephrogenic Anaemia |
5.6% |
| Dialysis |
5.0% |
| Hepatitis C |
4.7% |
| Hypertension |
3.6% |
| Myelodysplastic Syndrome |
2.8% |
| Renal Failure Chronic |
2.5% |
| Escherichia Infection |
1.7% |
| Prophylaxis |
1.7% |
| Anaemia Of Malignant Disease |
1.4% |
| Multiple Myeloma |
1.4% |
| Drug Therapy |
1.1% |
| Mantle Cell Lymphoma |
1.1% |
| Metastases To Liver |
1.1% |
| Thrombosis Prophylaxis |
1.1% |
|
| Aplasia Pure Red Cell |
15.0% |
| Drug Ineffective |
12.5% |
| Status Epilepticus |
10.0% |
| Thrombosis |
10.0% |
| Therapeutic Response Decreased |
8.8% |
| Pancytopenia |
5.0% |
| Sepsis |
5.0% |
| Visceral Arterial Ischaemia |
5.0% |
| Acute Coronary Syndrome |
2.5% |
| Blindness |
2.5% |
| Cardiac Failure Congestive |
2.5% |
| Colitis |
2.5% |
| Gastrointestinal Necrosis |
2.5% |
| Lung Adenocarcinoma Metastatic |
2.5% |
| Muscle Spasms |
2.5% |
| Nephrogenic Systemic Fibrosis |
2.5% |
| Renal Failure Acute |
2.5% |
| Renal Failure Chronic |
2.5% |
| Urinary Tract Infection |
2.5% |
| Anaemia |
1.3% |
|
| Concomitant |
| Product Used For Unknown Indication |
31.0% |
| Drug Use For Unknown Indication |
27.5% |
| Nuclear Magnetic Resonance Imaging |
5.3% |
| Hypertension |
4.9% |
| Anaemia |
4.4% |
| Multiple Myeloma |
3.4% |
| Prophylaxis |
3.4% |
| Pain |
3.1% |
| Hyperparathyroidism Secondary |
2.4% |
| Hepatitis C |
2.0% |
| Non-small Cell Lung Cancer |
1.9% |
| Hiv Infection |
1.6% |
| Diabetes Mellitus |
1.3% |
| Premedication |
1.2% |
| Angiogram |
1.2% |
| Renal Failure Chronic |
1.2% |
| Constipation |
1.2% |
| Coronary Artery Disease |
1.0% |
| Chemotherapy |
1.0% |
| Thrombosis Prophylaxis |
1.0% |
|
| Vomiting |
9.4% |
| Renal Failure |
7.9% |
| Thrombocytopenia |
7.9% |
| Nephrogenic Systemic Fibrosis |
7.1% |
| Skin Tightness |
6.4% |
| Sepsis |
5.6% |
| Pneumonia |
5.2% |
| Renal Failure Acute |
5.2% |
| Leukopenia |
4.9% |
| Pyrexia |
4.5% |
| Respiratory Arrest |
4.5% |
| Ventricular Hypertrophy |
4.1% |
| Weight Decreased |
4.1% |
| Diarrhoea |
3.7% |
| Neutropenia |
3.7% |
| Pain |
3.7% |
| Infection |
3.0% |
| Septic Shock |
3.0% |
| Urinary Tract Infection |
3.0% |
| Wound |
3.0% |
|
